Basic Information
RNALocate ID: | RLID:01001773 |
RNA Symbol: | hsa-miR-132-3p |
Localization: | Nucleus |
RNA Information
RNA Name: | hsa-miR-132 |
RNA ID: | miRBase:MIMAT0000426 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 27583637 |
Tissue/Cell Line: | Human neuroblastoma cell line (SK-N-AS) |
Method: | Confocal fluorescence microscopy|Live cell imaging |
Description: | miR-132 appears to be localized within the nucleus of the cells, where its concentration is of the order of 1 μM. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001770 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001771 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01001772 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:11001736 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11001737 | Exosome | Ovarian follicular fluid | 22116803 |
RLID:11001738 | Exosome | Breast milk | 22211110 |
RLID:11001739 | Exosome | Brain tissue | 23382797 |
RLID:11001740 | Exosome | Plasma | 23663360 |
RLID:11001741 | Extracellular vesicle | HEK-293T cells | 22849433 |
RLID:11001742 | Microvesicle | Seminal plasma | 23539611 |
RLID:11001743 | Microvesicle | Follicular fluid | 23666971 |
RLID:11001744 | Microvesicle | Cerebrospinal fluid | 24797360 |
RLID:11005568 | Exosome | Peripheral blood | 32785072 |
RLID-D:11000079 | Exosome | Blood|Endothelial cells|Mast cells | |
RLID-D:11000354 | Microvesicle | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-132-3p | Inflammatory bowel disease | MNDR-E-MI-11225 |
MNDR | hsa-miR-132-3p | Splenic marginal zone lymphoma | MNDR-E-MI-11226 |
MNDR | hsa-miR-132-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-11227 |
MNDR | hsa-miR-132-3p | Oral squamous cell carcinoma | MNDR-E-MI-11228 |
MNDR | hsa-miR-132-3p | Medulloblastoma | MNDR-E-MI-11229 |
MNDR | hsa-miR-132-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-11230 |
MNDR | hsa-miR-132-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-11231 |
MNDR | hsa-miR-132-3p | Lymphoma | MNDR-E-MI-11232 |
MNDR | hsa-miR-132-3p | Lymphoma non-hodgkin | MNDR-E-MI-11233 |
MNDR | hsa-miR-132-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-11234 |
MNDR | hsa-miR-132-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-11235 |
MNDR | hsa-miR-132-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-11236 |
MNDR | hsa-miR-132-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-11237 |
MNDR | hsa-miR-132-3p | Her2-receptor positive breast cancer | MNDR-E-MI-11238 |
MNDR | hsa-miR-132-3p | Anencephaly | MNDR-E-MI-11239 |
MNDR | hsa-miR-132-3p | Familial temporal lobe epilepsy 3 | MNDR-E-MI-11240 |
MNDR | hsa-miR-132-3p | Autosomal recessive limb-girdle muscular dystrophy type 2a | MNDR-E-MI-11241 |
MNDR | hsa-miR-132-3p | Dermatomyositis | MNDR-E-MI-11242 |
MNDR | hsa-miR-132-3p | Prostate cancer | MNDR-E-MI-11243 |
MNDR | hsa-miR-132-3p | Chronic lymphocytic leukemia | MNDR-E-MI-11244 |
MNDR | hsa-miR-132-3p | Gastric cancer | MNDR-E-MI-11245 |
MNDR | hsa-miR-132-3p | Gastric lymphoma | MNDR-E-MI-11246 |
MNDR | hsa-miR-132-3p | Alzheimer disease | MNDR-E-MI-11247 |
MNDR | hsa-miR-132-3p | Bladder cancer | MNDR-E-MI-11248 |
MNDR | hsa-miR-132-3p | Dysautonomia familial | MNDR-E-MI-11249 |
MNDR | hsa-miR-132-3p | Facioscapulohumeral muscular dystrophy | MNDR-E-MI-11250 |
MNDR | hsa-miR-132-3p | Friedreich ataxia | MNDR-E-MI-11251 |
MNDR | hsa-miR-132-3p | Huntington disease | MNDR-E-MI-11252 |
MNDR | hsa-miR-132-3p | Chorea | MNDR-E-MI-11253 |
MNDR | hsa-miR-132-3p | Cardiovascular disease | MNDR-E-MI-11254 |
MNDR | hsa-miR-132-3p | Lung cancer | MNDR-E-MI-11255 |
MNDR | hsa-miR-132-3p | Down syndrome | MNDR-E-MI-11256 |
MNDR | hsa-miR-132-3p | Fragile x syndrome | MNDR-E-MI-11257 |
MNDR | hsa-miR-132-3p | Parkinson disease | MNDR-E-MI-11258 |
MNDR | hsa-miR-132-3p | Cognitive dysfunction | MNDR-E-MI-11259 |
MNDR | hsa-miR-132-3p | Breast cancer | MNDR-E-MI-11260 |
MNDR | hsa-miR-132-3p | Thyroid cancer | MNDR-E-MI-11261 |
MNDR | hsa-miR-132-3p | Pituitary neoplasms | MNDR-E-MI-11262 |
MNDR | hsa-miR-132-3p | Pancreatic cancer | MNDR-E-MI-11263 |
MNDR | hsa-miR-132-3p | Melanoma | MNDR-E-MI-11264 |
MNDR | hsa-miR-132-3p | Rectum adenocarcinoma | MNDR-E-MI-11265 |
MNDR | hsa-miR-132-3p | Nephroblastoma | MNDR-E-MI-11266 |
MNDR | hsa-miR-132-3p | Colon cancer | MNDR-E-MI-11267 |
MNDR | hsa-miR-132-3p | Colon adenocarcinoma | MNDR-E-MI-11268 |
MNDR | hsa-miR-132-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-11269 |
MNDR | hsa-miR-132-3p | Prostate adenocarcinoma | MNDR-E-MI-11270 |
MNDR | hsa-miR-132-3p | Endometrial carcinoma | MNDR-E-MI-11271 |
MNDR | hsa-miR-132-3p | Carcinoma ductal breast | MNDR-E-MI-11272 |
MNDR | hsa-miR-132-3p | Glioblastoma | MNDR-E-MI-11273 |
MNDR | hsa-miR-132-3p | Glioma | MNDR-E-MI-11274 |
MNDR | hsa-miR-132-3p | Chronic obstructive pulmonary disease | MNDR-E-MI-11275 |
MNDR | hsa-miR-132-3p | Oligodendroglioma | MNDR-E-MI-11276 |
MNDR | hsa-miR-132-3p | Nemaline myopathy | MNDR-E-MI-11277 |
MNDR | hsa-miR-132-3p | Chordoma | MNDR-E-MI-11278 |
MNDR | hsa-miR-132-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-11279 |
MNDR | hsa-miR-132-3p | Epilepsy temporal lobe | MNDR-E-MI-11280 |
MNDR | hsa-miR-132-3p | Osteosarcoma | MNDR-E-MI-11281 |
MNDR | hsa-miR-132-3p | Liver neoplasms | MNDR-E-MI-11282 |
MNDR | hsa-miR-132-3p | Uterine cancer | MNDR-E-MI-11283 |
MNDR | hsa-miR-132-3p | Gastric adenocarcinoma | MNDR-E-MI-11284 |
MNDR | hsa-miR-132-3p | Cervical squamous cell carcinoma | MNDR-E-MI-11285 |
MNDR | hsa-miR-132-3p | Pituitary adenoma | MNDR-E-MI-11286 |
MNDR | hsa-miR-132-3p | Craniopharyngioma | MNDR-E-MI-11287 |
MNDR | hsa-miR-132-3p | Lung squamous cell carcinoma | MNDR-E-MI-11288 |
MNDR | hsa-miR-132-3p | Carcinoma lung non-small-cell | MNDR-E-MI-11289 |
MNDR | hsa-miR-132-3p | Lung adenocarcinoma | MNDR-E-MI-11290 |
MNDR | hsa-miR-132-3p | Thyroid carcinoma | MNDR-E-MI-11291 |
MNDR | hsa-miR-132-3p | Ovarian carcinoma | MNDR-E-MI-11292 |
MNDR | hsa-miR-132-3p | Bladder urothelial carcinoma | MNDR-E-MI-11293 |
MNDR | hsa-miR-132-3p | Pancreatic adenocarcinoma | MNDR-E-MI-11294 |
MNDR | hsa-miR-132-3p | Carcinoma renal cell | MNDR-E-MI-11295 |
MNDR | hsa-miR-132-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-11296 |
MNDR | hsa-miR-132-3p | Cholangiocarcinoma | MNDR-E-MI-11297 |
MNDR | hsa-miR-132-3p | Esophageal cancer | MNDR-E-MI-11298 |
MNDR | hsa-miR-132-3p | Encephalopathy bovine spongiform | MNDR-E-MI-11299 |
MNDR | hsa-miR-132-3p | Synovial sarcoma | MNDR-E-MI-11300 |
MNDR | hsa-miR-132-3p | T acute lymphoblastic leukemia | MNDR-E-MI-11301 |
MNDR | hsa-miR-132-3p | Acute t cell leukemia | MNDR-E-MI-11302 |
MNDR | hsa-miR-132-3p | Breast invasive carcinoma | MNDR-E-MI-11303 |
MNDR | hsa-miR-132-3p | Juvenile rheumatoid arthritis | MNDR-E-MI-11304 |
MNDR | hsa-miR-132-3p | Progressive supranuclear palsy | MNDR-E-MI-11305 |
MNDR | hsa-miR-132-3p | Hepatocellular carcinoma | MNDR-E-MI-11306 |
MNDR | hsa-miR-132-3p | Liver carcinoma | MNDR-E-MI-11307 |
MNDR | hsa-miR-132-3p | Embryonal cancer | MNDR-E-MI-11308 |
MNDR | hsa-miR-132-3p | B-cell non-hodgkin lymphoma | MNDR-E-MI-11309 |
MNDR | hsa-miR-132-3p | Rheumatoid arthritis | MNDR-E-MI-11310 |
MNDR | hsa-miR-132-3p | T-cell leukemia | MNDR-E-MI-11311 |
MNDR | hsa-miR-132-3p | Malignant pleural mesothelioma | MNDR-E-MI-11312 |
MNDR | hsa-miR-132-3p | Neuroblastoma | MNDR-E-MI-11313 |
MNDR | hsa-miR-132-3p | Hodgkin lymphoma | MNDR-E-MI-11314 |
MNDR | hsa-miR-132-3p | Burkitt lymphoma | MNDR-E-MI-11315 |
MNDR | hsa-miR-132-3p | Neuromyelitis optica | MNDR-E-MI-11316 |
MNDR | hsa-miR-132-3p | Acute myelogenous leukemia | MNDR-E-MI-11317 |
MNDR | hsa-miR-132-3p | Frontotemporal dementia | MNDR-E-MI-11318 |
MNDR | hsa-miR-132-3p | Colorectal cancer | MNDR-E-MI-11319 |
MNDR | hsa-miR-132-3p | Nasopharynx carcinoma | MNDR-E-MI-11320 |
MNDR | hsa-miR-132-3p | Ependymoma | MNDR-E-MI-11321 |
MNDR | hsa-miR-132-3p | Nasopharyngeal cancer | MNDR-E-MI-11322 |
MNDR | hsa-miR-132-3p | Sleep deprivation | MNDR-E-MI-11323 |
MNDR | hsa-miR-132-3p | Toxoplasmosis cerebral | MNDR-E-MI-11324 |
MNDR | hsa-miR-132-3p | Polymyositis | MNDR-E-MI-11325 |
MNDR | hsa-miR-132-3p | Epstein-barr virus infections | MNDR-E-MI-11326 |
MNDR | hsa-miR-132-3p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-11327 |
MNDR | hsa-miR-132-3p | Gait ataxia | MNDR-E-MI-11328 |
MNDR | hsa-miR-132-3p | Lung injury | MNDR-E-MI-11329 |
MNDR | hsa-miR-132-3p | Chronic pain | MNDR-E-MI-11330 |
MNDR | hsa-miR-132-3p | Non-alcoholic fatty liver disease | MNDR-E-MI-11331 |
MNDR | hsa-miR-132-3p | Breast cancer her3+ negative | MNDR-E-MI-11332 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | AGO2 | Homo sapiens | RR00055673 |
TOP